Hainsworth J D, Johnson D H, Frazier S R, Greco F A
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Eur J Cancer. 1990;26(7):818-21. doi: 10.1016/0277-5379(90)90160-u.
In a phase II study, 25 patients with previously treated lymphoma received oral etoposide for 21 consecutive days. All patients were considered incurable with standard therapy. Etoposide was administered at 50 mg/m2 per day: courses were repeated every 28-35 days, depending on myelosuppression. 15 patients (60%) had partial responses (95% CI 41-77%), while 10 patients had no response. Median time to disease progression was 5 months (range 2-13 months). Oral etoposide was active against indolent and aggressive (intermediate and high grade) lymphomas; however, median time to progression was only 3 months in aggressive lymphoma compared with 8 months in indolent lymphoma. Myelosuppression was the major side-effect; 7 patients (28%) had a leucocyte nadir below 1000/microliters during the first course, and 11 patients required dose reduction during subsequent courses due to unacceptable leukopenia. All patients had total alopecia, but other side-effects were uncommon. These results highlight the importance of schedule in the administration of etoposide.
在一项II期研究中，25例先前接受过治疗的淋巴瘤患者连续21天口服依托泊苷。所有患者被认为无法通过标准疗法治愈。依托泊苷的给药剂量为每天50mg/m²：疗程根据骨髓抑制情况每28 - 35天重复一次。15例患者（60%）有部分缓解（95%可信区间41 - 77%），而10例患者无反应。疾病进展的中位时间为5个月（范围2 - 13个月）。口服依托泊苷对惰性淋巴瘤和侵袭性（中、高级别）淋巴瘤均有活性；然而，侵袭性淋巴瘤的中位进展时间仅为3个月，而惰性淋巴瘤为8个月。骨髓抑制是主要副作用；7例患者（28%）在第一个疗程期间白细胞最低点低于1000/微升，11例患者在随后的疗程中因不可接受的白细胞减少而需要减少剂量。所有患者均出现完全脱发，但其他副作用并不常见。这些结果突出了依托泊苷给药方案的重要性。
